Dinalbuphine sebacate - Lumosa Therapeutics

Drug Profile

Dinalbuphine sebacate - Lumosa Therapeutics

Alternative Names: LT 1001; Naldebain; SDE; Sebocoyl dinalbuphine ester

Latest Information Update: 31 Aug 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Lumosa Therapeutics
  • Class Analgesics; Esters; Ethers; Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid kappa receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Pain

Most Recent Events

  • 28 Aug 2017 Lumosa Therapeutics and Camargo Pharmaceutical Services agree to co-develop dinalbuphine sebacate in USA for Pain
  • 03 Aug 2017 Dinalbuphine sebacate is still in phase-II/III development for Pain in Taiwan (Lumosa Therapeutics website, August 2017)
  • 03 Aug 2017 Dinalbuphine sebacate is available for licensing as of 03 Aug 2017. www.lumosa.com
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top